# US 11,110,075 B2 · Use of daphnetin in improving function of aortic endothelial cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,075 B2
- Document ID: US11110075B2
- Status: Granted
- Kind: B2
- Application number: 16/659,477
- Filed: 2019-10-21
- Published: 2021-02-18
- Granted: 2021-09-07
- Earliest claimed: 2019-08-14
- Assignees: Xi'an Jiaotong University
- Applicants: Xi'an Jiaotong University
- Inventors: Jian-Gang Long; Xu-Yun Liu; Jian-Kang Liu
- Web page: https://patentgrep.com/patent/US11110075B2

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The disclosure relates to a pharmaceutical composition including daphnetin, a method for improving aortic endothelial cell function, and use of daphnetin in preparation of a medicine for improving aortic endothelial cell function. The daphnetin is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The daphnetin is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid.

## Claims

### Claim 1

A method for improving function of an aortic endothelial cell, the method comprising contacting the cell with an effective amount of daphnetin.

### Claim 2 (depends on 1)

The method for claim 1, wherein the daphnetin inhibits saturated fatty acid induced inflammation of an aortic endothelial cell.

### Claim 3 (depends on 1)

The method for claim 1, wherein the daphnetin reduces a mRNA level corresponding to interleukin-6 in an aortic endothelial cell.

### Claim 4 (depends on 1)

The method for claim 1, wherein the daphnetin protects a mitochondrion from being damaged by saturated fatty acid induced inflammation of an aortic endothelial cell.

### Claim 5 (depends on 1)

The method for claim 1, wherein the daphnetin increases an expression of mitochondrial complex I protein in an aortic endothelial cell.